The company has developed a proprietary platform called CASi, which combines the advantages of single and double-stranded RNAs in a single molecule, allowing for targeted RNAi activity. With $52M in funding, Switch Therapeutics is focused on treating diseases affecting the central nervous system and systemic indications with unmet needs. Their research is based on technology developed by renowned researchers from Caltech, Harvard, and City of Hope.